• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

    10/6/23 5:10:06 PM ET
    $IMPL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $IMPL alert in real time by email
    SC 13D/A 1 ef20011968_sc13da.htm SC 13D/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13D

    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)


    IMPEL PHARMACEUTICALS INC.
    (Name of Issuer)

    Common Stock, $0.001 par value per share
    (Title of Class of Securities)

    45258K109
    (CUSIP Number)

    Todd E. Molz
    General Counsel, Chief Administrative Officer & Managing Director
    Oaktree Capital Group Holdings GP, LLC
    333 South Grand Avenue, 28th Floor
    Los Angeles California 90071
    (213) 830-6300

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    October 2, 2023
    (Date of Event Which Requires Filing of This Statement)



    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See Rule 13d-7 for other parties to whom copies are to be sent.


    *
    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    Page 2 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-TCDRS Strategic Credit, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not Applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    24,402 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    24,402 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    24,402 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.09% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)
    The reported securities represent 24,402 shares of common stock of the Issuer (“Common Stock”) issuable upon the exercise of currently exercisable Warrants (as defined below) directly held by the Reporting Person.

    (2)
    Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.

    2

    Page 3 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-Forrest Multi-Strategy, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Maryland
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    19,727 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    19,727 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    19,727 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.08% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 19,727 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 4 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-TBMR Strategic Credit Fund C, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    11,867 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    11,867 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    11,867 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.05% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 11,867 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 5 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-TBMR Strategic Credit Fund F, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    18,591 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    18,591 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    18,591 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.07% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 18,591 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 6 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-TBMR Strategic Credit Fund G, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    30,347 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    30,347 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    30,347 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.12% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 30,347 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 7 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree-TSE 16 Strategic Credit, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    30,547 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    30,547 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    30,547 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.12% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 30,547 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 8 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    INPRS Strategic Credit Holdings, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    9,039 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    9,039 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    9,039 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.03% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 9,039 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 9 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Gilead Investment Fund AIF (Delaware), L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    152,892 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    152,892 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    152,892 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.59% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 152,892 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)         Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 10 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Specialty Lending Corporation
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    583,736 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    583,736 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    583,736 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    2.25% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1)          The reported securities represent 583,736 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 11 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Strategic Credit Fund
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    212,294 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    212,294 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    212,294 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.82% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 212,294 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 12 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree GCP Fund Delaware Holdings, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    13,581 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    13,581 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    13,581 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.05% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 13,581 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 13 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Diversified Income Fund Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    44,574 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    44,574 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    44,574 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.17% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     

    (1)          The reported securities represent 44,574 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 14 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree AZ Strategic Lending Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    290,398 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    290,398 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    290,398 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.12% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 290,398 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 15 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Loan Acquisition Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    135,861 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    135,861 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    135,861 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.52% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 135,861 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 16 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree LSL Fund Holdings EURRC S.à r.l.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Luxembourg
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    288,704 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    288,704 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    288,704 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    1.11% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 288,704 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 17 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree LSL Fund Delaware Holdings EURRC, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    169,835 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    169,835 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    169,835 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.65% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 169,835 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 18 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree PRE Life Sciences Fund, L.P.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    190,074 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    190,074 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    190,074 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.73% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    PN
     
     
     
     

    (1)          The reported securities represent 190,074 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Reporting Person.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 19 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Oaktree Capital Group, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    212,294 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    212,294 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    212,294 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.82% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 212,294 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by Oaktree Strategic Credit Fund.

    (2)          Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 20 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Atlas OCM Holdings, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,014,175 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,014,175 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,014,175 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.75% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 2,014,175 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Atlas Entities (defined below).

    (2)       Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 21 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Brookfield Corporation
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Ontario, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    212,294 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    212,294 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    212,294 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.82% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 212,294 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by Oaktree Strategic Credit Fund.

    (2)       Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 22 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    BAM Partners Trust
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Ontario, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    212,294 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    212,294 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    212,294 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    0.82% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 212,294 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by Oaktree Strategic Credit Fund.

    (2)       Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 23 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    1
    NAMES OF REPORTING PERSONS
     
     
    Brookfield Asset Management ULC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a)
    ☐

    (b)
    ☒
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    SOURCE OF FUNDS (SEE INSTRUCTIONS)
     
     
    Not applicable
     
     
     
     
    5
    CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEM 2(D) OR 2(E)
     
    ☐

     
     
     
     
    6
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    British Columbia, Canada
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    7
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    8
    SHARED VOTING POWER
     
     
    2,014,175 (1)
     
     
     
     
    9
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    10
    SHARED DISPOSITIVE POWER
     
     
    2,014,175 (1)
     
     
     
     
    11
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    2,014,175 (1)
     
     
     
     
    12
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
    ☐

     
     
     
     
    13
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
     
     
    7.75% (2)
     
     
     
     
    14
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     

    (1)          The reported securities represent 2,014,175 shares of Common Stock issuable upon the exercise of currently exercisable Warrants directly held by the Atlas Entities (defined below).

    (2)       Calculations of percentage ownership are based on a total of 25,975,474 shares of Common Stock, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 14, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants beneficially owned by the Reporting Persons.


    Page 24 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    Explanatory Note

    This Amendment No. 1 (this “Amendment No. 1”) to the statement of beneficial ownership on Schedule 13D amends and supplements the statement of beneficial ownership on Schedule 13D filed by the Reporting Persons on September 15, 2023 (the “Original Schedule 13D”, and together with this Amendment No. 1, the “Schedule 13D”). Except as amended in this Amendment No. 1, the Original Schedule 13D remains in full force and effect. Terms defined in the Original Schedule 13D are used in this Amendment No. 1 as so defined in the Original Schedule 13D, unless otherwise defined in this Amendment No. 1.

    Item 3.
    Source and Amount of Funds or Other Consideration.

    Item 3 is hereby amended to add the following after the second sentence of Item 3 of the Original Schedule 13D:

    In addition, on October 2, 2023, the Issuer issued to the Oaktree Holders immediately exercisable warrants to acquire an aggregate of 445,293 shares of Common Stock at an exercise price per share of $0.01, in connection with the Issuer’s borrowing of an additional $2.5 million in aggregate principal amount of tranche B term loans.

    Item 4.
    Purpose of Transaction

     Item 4 is hereby amended and restated in its entirety as follows:

    Amended Credit Agreement

    Second Amendment

    On September 5, 2023, the Issuer entered into the Second Amendment to Credit Agreement and Guaranty and Revenue Interest Financing Agreement (the “Second Amendment”) with Oaktree Fund Administration, LLC as administrative agent (the “Administrative Agent”), the Oaktree Holders, as existing lenders, and certain other lenders party thereto (collectively, the “Lenders”), which amends the Issuer’s (i) Credit Agreement and Guaranty dated March 17, 2022, as amended on August 21, 2023 (the “Original Agreement” and, as amended by the Second Amendment and the Third Amendment (as defined below), the “Amended Credit Agreement”), and (ii) the Revenue Interest Financing Agreement dated March 17, 2022, as amended on August 21, 2023. The Amended Credit Agreement provides for an aggregate principal loan amount to the Issuer by the Lenders of approximately $121.5 million, including up to $20 million in additional cash proceeds to the Issuer from the making of additional term loans, the exchange of approximately $96.5 million of outstanding principal under the Original Agreement, and an in-kind forbearance fee of $5.0 million.


    Page 25 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    Pursuant to the Second Amendment, the Issuer borrowed $4,500,000 of tranche B term loans at signing (in addition to $3,000,000 previously funded on August 21, 2023) and was granted the right to draw up to $12,500,000 more in additional tranche B term loans over the course of 2023, subject to the Issuer’s achievement of certain strategic transaction process milestones, satisfaction of minimum net revenue and product units sold covenants and satisfaction of certain other covenants and conditions specified in the Second Amendment.

    Under the Second Amendment, the first lien tranche A provides for loans in an aggregate original principal loan of $101.5 million, consisting of $51.4 million exchanged for existing tranche A-1 term loans, a $5.0 million forbearance fee, $9.1 million exchanged for existing tranche A-2 term loans, and $36.0 million exchanged for the right to future revenue interest payments. The first lien tranche B provides for loans in an aggregate original principal loan of $20.0 million.

    Interest will be paid in kind (PIK) on both the tranche A and tranche B term loans through the end of the forbearance period, which was extended to December 31, 2023, under the Second Amendment, and accrues at SOFR + 10.75%. The first lien tranche B is entitled to a 2x multiple on invested capital. The tranche A lenders and tranche B lenders will be entitled to be repaid a maximum aggregate amount of approximately $141.5 million (assuming the entire $20.0 million of tranche B loans are funded), plus PIK interest on the tranche A term loan.

    The amounts outstanding under the Second Amendment are secured and collateralized by all of the Issuer’s assets. The Second Amendment also provides for certain modifications to the existing covenants, including additional reporting obligations, minimum net revenue and product units sold covenants and additional milestones. In addition, the Second Amendment includes customary events of default, the occurrence of which could result in termination of the Lenders’ commitments or the acceleration of the Issuer’s obligations under the Second Amendment.

    The foregoing summary of the Second Amendment does not purport to be complete and is qualified in its entirety by the full text of the Second Amendment, which is filed hereto as Exhibit 2, and is incorporated herein by reference.

    Third Amendment

    On October 2, 2023, the Issuer entered into the Third Amendment (the “Third Amendment”) to the Amended Credit Agreement.

    Pursuant to the Third Amendment, the requisite Lenders waived certain defaults of the Issuer under the Amended Credit Agreement. Under the Third Amendment, terms of the tranche B term loans funding were modified and the Issuer drew an additional $5 million of tranche B term loans in connection with signing of the Third Amendment (of which the Oaktree Holders funded $1.875 million on October 2, 2023 and $1.875 million on October 6, 2023). The Issuer continues to have the right to draw up to an additional $7.5 million in tranche B term loans over the course of 2023, subject to the Issuer’s achievement of certain strategic milestones, satisfaction of minimum net revenue and product units sold covenants and satisfaction of certain other covenants and conditions as further amended in the Third Amendment.

    The Third Amendment further provides that the Issuer shall use best efforts, subject to applicable law and fiduciary duties, to consummate an equity financing prior to October 31, 2023, and that to the extent proceeds from such financing exceed $5 million the Issuer will apply 50% of such excess proceeds to repay the tranche B term loans.

    The Third Amendment further provides that the Issuer will, no later than October 16, 2023, appoint one additional independent director (the “Designee”) to the Issuer’s Board of Directors, with support and approval by the Administrative Agent and a majority of the Lenders (which includes the Oaktree Holders), who shall (i) be entitled to reasonable and customary compensation and indemnification arrangements at the expense of the Issuer and (ii) be available to serve on any committees or subcommittees, including any committees overseeing, coordinating or implementing matters relating to the Issuer’s capital structure, any restructuring, any equity raise and any sale or business combination transaction. The Third Amendment further provides that if the Designee is unable or unwilling to serve and ceases to be a director, resigns as a director or is removed as a director, or for any other reason fails to serve or is not serving as a director, the Issuer agrees to cause the appointment to the Board of a new independent director in substantially the same manner as the Issuer, the Administrative Agent and a majority of the Lenders (which includes the Oaktree Holders) agreed upon the selection of such Designee.


    Page 26 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    The foregoing summary of the Third Amendment does not purport to be complete and is qualified in its entirety by the full text of the Third Amendment, which is filed hereto as Exhibit 4, and is incorporated herein by reference.

    Warrants

    Pursuant to the Amended Credit Agreement, the Issuer agreed to issue to the tranche B lenders, from time to time, warrants to purchase up to an aggregate of 4,749,800 shares of Common Stock, representing warrant coverage equal to an aggregate 19.99% of the Issuer’s outstanding shares of Common Stock as of the date thereof (the “Tranche B Warrants”). The Tranche B Warrants are to be issued to each tranche B lender upon each borrowing of tranche B term loans in proportion to the amount of tranche B term loans funded by such tranche B lender. In consideration for the funding of $4.5 million and $3 million of tranche B term loans on September 5, 2023 and August 21, 2023, respectively, or 37.5% of the original principal amount of the tranche B term loan, Tranche B Warrants exercisable for an aggregate of 1,781,175 shares of Common Stock, or 37.5% of the aggregate warrant coverage amount, were issued to the tranche B lenders at signing of the Second Amendment on September 5, 2023. The Issuer agreed that Tranche B Warrants exercisable for up to the remaining 2,968,625 shares of Common Stock, or 62.5% of the aggregate warrant coverage amount, would be issued to the tranche B lenders on a pro rata basis in connection with each subsequent draw, if any, by the Issuer of the tranche B term loans as described in the Amended Credit Agreement.

    In their capacity as tranche B lenders, the Oaktree Holders were issued Tranche B Warrants pursuant to warrant certificates exercisable for an aggregate of 1,335,881 shares of Common Stock at the signing of the Second Amendment on September 5, 2023 (the “Tranche 1 Warrants”). In connection with the Issuer’s draw of an additional $5 million of tranche B term loans in connection with the Third Amendment, the Oaktree Holders were issued additional Tranche B Warrants pursuant to warrant certificates exercisable for an aggregate of 890,588 shares of Common Stock (collectively and together with the Tranche 1 Warrants, the “Warrants”). The Oaktree Holders may be issued additional Tranche B Warrants exercisable for up to an additional 1,335,881 shares of Common Stock from time to time as provided in the Amended Credit Agreement.

    The Warrants are exercisable, in full or in part, at any time prior to the seventh (7th) anniversary of their issuance or the consummation of a Change of Control (as defined in the Warrants), whichever occurs earlier, at an exercise price of $0.01 per share, provided that for so long as the Common Stock is listed on a public trading exchange, unless and until the Issuer obtains shareholder approval, the Warrants may only be exercised to the extent all Tranche B Warrants then outstanding are simultaneously exercised in accordance with their terms. The Warrants are subject to anti-dilution adjustments in the event of certain future subdivisions (by any stock split, recapitalization or otherwise), combinations or similar events, any capital reorganization, reclassification, consolidation or merger or other similar transaction of the Issuer that does not constitute a Change of Control as set forth in the Warrants. The Warrants may be exercised for cash in an amount equal to the aggregate exercise price, or in lieu of paying the aggregate exercise price, the Oaktree Holders may elect a cashless exercise in accordance with the terms of the Warrants. Prior to the issuance of shares of Common Stock upon exercise of the Warrants, the Oaktree Holders are not entitled to vote or be deemed the holder of shares of Common Stock, however the Oaktree Holders are entitled to receive, simultaneously with holders of the Common Stock, dividends and other distributions made to such holders of Common Stock.

    Pursuant to the terms of the Warrants, the Oaktree Holders and their affiliates will be entitled to registration rights under certain circumstances in connection with the exercise of the Warrants and the issuance of the shares of Common Stock thereunder.


    Page 27 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    The foregoing description of the Warrants does not purport to be complete and is qualified in its entirety by the full text of the Form of Warrant, which is filed hereto as Exhibit 3, and is incorporated herein by reference.

    General

    Each of the Reporting Persons acquired the Warrants for investment purposes. The Reporting Persons will continuously evaluate the Issuer’s businesses, strategies, prospects, management, governance, operations, performance, financial matters, capital structure and prospects, market positions, strategic and other transactions (including transactions involving one or more of the Reporting Persons and/or their respective affiliates and/or portfolio companies and/or other stockholders of the Issuer), director and officer incentive programs, corporate governance decisions by the Issuer’s management and the Board of Directors of the Issuer (the “Board”), alternative investment opportunities, changes in law and/or regulations, general industry or economic conditions and all other factors that may increase the value of the Issuer’s securities beneficially owned by the Reporting Persons or that may be deemed relevant in determining whether additional securities will be acquired by the Reporting Persons or, if applicable, their affiliates or whether the Reporting Persons or, if applicable, any such affiliates will dispose of shares of Common Stock or other securities of the Issuer. Depending on such factors, at any time, the Reporting Persons may acquire shares of Common Stock or other securities of the Issuer in addition to the shares of Common Stock underlying the Warrants, including, without limitation, a controlling position in the Common Stock or some or all of the shares of Common Stock or other securities that are beneficially owned by the Reporting Persons may be sold, in either case in the open market, in privately negotiated transactions or otherwise. The Reporting Persons may also seek to modify the terms of the Issuer’s securities held by them, through various transactions, including, without limitation, refinancing or derivative transactions, provide additional capital or debt financing to the Issuer, or pledge their interests in the Issuer’s securities as collateral for liquidity purposes.

    Other than as described in this Schedule 13D, none of the Reporting Persons and, to the best of their knowledge, none of the Covered Persons has any current plans or proposals which relate to or would result in any of the matters described in Items 4(a)-(j) of Schedule 13D. However, as part of their ongoing evaluation of their investment in the Issuer and investment alternatives, the Reporting Persons may consider such matters in the future and, subject to applicable law, may formulate a plan with respect to such matters, and, from time to time, the Reporting Persons may hold discussions with or make informal recommendations or formal proposals to Issuer’s management or the Board, including any special committees of the Board and their respective advisors, other holders of the Issuer’s securities, industry analysts, financial sponsors, existing or potential strategic partners, sources or potential sources of capital and other third parties regarding such matters.

    Item 5.
    Interest in Securities of the Issuer.

    Item 5 is hereby amended and restated in its entirety as follows:

    (a) and (b).

    The information contained on the cover pages of this Schedule 13D is incorporated herein by reference.

    Pursuant to Rule 13d-4 of the Act, the Reporting Persons declare that filing this statement shall not be construed as an admission that any such person is, for the purposes of Section 13(d) and/or Section 13(g) of the Act, the beneficial owner of any securities covered by this statement.


    Page 28 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    In the aggregate, the Reporting Persons beneficially own, as of the date hereof, 2,226,469 shares of Common Stock by virtue of the Warrants directly held by the Oaktree Holders as described below. The Warrants are immediately exercisable for 2,226,469 shares of Common Stock, representing approximately 8.57% of the Common Stock outstanding as of the date hereof.
     
    All such ownership percentages of the securities reported herein are based upon 25,975,474 shares of Common Stock outstanding, calculated based on the sum of (i) 23,749,005 shares of Common Stock issued and outstanding as of August 15, 2023, as reported by the Issuer in its Form 10-Q filed with the SEC on August 18, 2023, and (ii) 2,226,469 shares of Common Stock issuable upon full exercise of the Warrants held by the Oaktree Holders.
     
    Oaktree-TCDRS Strategic Credit, LLC directly holds Warrants exercisable immediately for 24,402 shares of Common Stock;
     
    Oaktree-Forrest Multi-Strategy, LLC directly holds Warrants exercisable immediately for 19,727 shares of Common Stock;
     
    Oaktree-TBMR Strategic Credit Fund C, LLC directly holds Warrants exercisable immediately for 11,867 shares of Common Stock;
     
    Oaktree-TBMR Strategic Credit Fund F, LLC directly holds Warrants exercisable immediately for 18,591 shares of Common Stock;
     
    Oaktree-TBMR Strategic Credit Fund G, LLC directly holds Warrants exercisable immediately for 30,347 shares of Common Stock;
     
    Oaktree-TSE 16 Strategic Credit, LLC directly holds Warrants exercisable immediately for 30,547 shares of Common Stock;
     
    INPRS Strategic Credit Holdings, LLC directly holds Warrants exercisable immediately for 9,039 shares of Common Stock;
     
    Oaktree Gilead Investment Fund AIF (Delaware), L.P. directly holds Warrants exercisable immediately for 152,892 shares of Common Stock;
     
    Oaktree Specialty Lending Corporation directly holds Warrants exercisable immediately for 583,736 shares of Common Stock;
     
    Oaktree Strategic Credit Fund directly holds Warrants exercisable immediately for 212,294 shares of Common Stock;
     
    Oaktree GCP Fund Delaware Holdings, L.P. directly holds Warrants exercisable immediately for 13,581 shares of Common Stock;
     
    Oaktree Diversified Income Fund Inc., directly holds Warrants exercisable immediately for 44,574 shares of Common Stock;
     
    Oaktree AZ Strategic Lending Fund, L.P. directly holds Warrants exercisable immediately for 290,398 shares of Common Stock;
     
    Oaktree Loan Acquisition Fund, L.P. directly holds Warrants exercisable immediately for 135,861 shares of Common Stock;
     
    Oaktree LSL Fund Holdings EURRC S.à r.l., directly holds Warrants exercisable immediately for 288,704 shares of Common Stock;
     

    Page 29 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    Oaktree LSL Fund Delaware Holdings EURRC, L.P. directly holds Warrants exercisable immediately for 169,835 shares of Common Stock;
     
    Oaktree PRE Life Sciences Fund, L.P. directly holds Warrants exercisable immediately for 190,074 shares of Common Stock;
     
    Oaktree Capital Group, LLC, in its capacity as the indirect manager of Oaktree Strategic Credit Fund, may be deemed to beneficially own the 212,294 shares of Common Stock issuable upon exercise of the Warrants held directly by Oaktree Strategic Credit Fund;
     
    Atlas OCM Holdings, LLC in its capacity as the indirect manager of Oaktree-TCDRS Strategic Credit, LLC, Oaktree-Forrest Multi-Strategy, LLC, Oaktree-TBMR Strategic Credit Fund C, LLC, Oaktree-TBMR Strategic Credit Fund F, LLC, Oaktree-TBMR Strategic Credit Fund G, LLC, Oaktree-TSE 16 Strategic Credit, LLC, INPRS Strategic Credit Holdings, LLC, Oaktree Gilead Investment Fund AIF (Delaware), L.P., Oaktree Specialty Lending Corporation, Oaktree GCP Fund Delaware Holdings, L.P., Oaktree AZ Strategic Lending Fund, L.P., Oaktree Loan Acquisition Fund, L.P., Oaktree PRE Life Sciences Fund, L.P., Oaktree Diversified Income Fund Inc., Oaktree LSL Fund Holdings EURRC S.a r.l., and Oaktree LSL Fund Delaware Holdings EURRC, L.P. (the “Atlas Entities”), may be deemed to beneficially own the 2,014,175 shares of Common Stock issuable upon exercise of the Warrants held directly by the Atlas Entities;
     
    Brookfield Corporation, in its capacity as the indirect owner of the class A units of Oaktree Capital Group, LLC, may be deemed to beneficially own the 212,294 shares of Common Stock issuable upon exercise of the Warrants held directly by Oaktree Strategic Credit Fund;
     
    BAM Partners Trust, in its capacity as the sole owner of Class B Limited Voting Shares of Brookfield Corporation, may be deemed to beneficially own the 212,294 shares of Common Stock issuable upon exercise of the Warrants held directly by Oaktree Strategic Credit Fund; and
     
    Brookfield Asset Management ULC, in its capacity as the indirect owner of Class A units of Atlas OCM Holdings, LLC, may be deemed to beneficially own the 2,014,175 shares of Common Stock issuable upon exercise of the Warrants held directly by the Atlas Entities.

    With respect to the Warrants exercisable immediately for shares of Common Stock reported herein, each of the Reporting Persons may be deemed to have shared voting and dispositive power or the shared power to direct the vote and disposition of the number of Warrants exercisable immediately for shares of Common Stock which such Reporting Person may be deemed to beneficially own as set forth above.

    Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that it is the beneficial owner of any of the Warrants exercisable immediately for shares of Common Stock referred to herein for the purposes of Section 13(d) of the Act, or for any other purpose, and such beneficial ownership is expressly disclaimed by each Reporting Person, other than each Oaktree Holder with respect to securities reported as directly held by such Oaktree Holder.

    (c)

    Other than as set forth in this Schedule 13D, the Reporting Persons have not effected any transactions related to the Common Stock during the past 60 days.

    (d) and (e)

    Not applicable.


    Page 30 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    Item 6.
    Contracts, Arrangement, Understandings or Relationships with Respect to Securities of the Issuer.

    Item 6 is hereby amended and supplemented to incorporate by reference the information in Item 4 of this Schedule 13D.

    Item 7.
    Material to be Filed as Exhibits.

    Item 7 is hereby amended and supplemented by adding the following exhibits as the end thereof:


    Exhibit 4
    Third Amendment to Credit Agreement dated
    October 2, 2023 (incorporated by reference to Exhibit 10.1 to the Issuer’s Current Report on Form 8-K filed on October 4, 2023).


    Page 31 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
    Schedule 13D

    SIGNATURES

    After reasonable inquiry and to the best of our knowledge and belief, we certify that the information set forth in this statement is true, complete and correct.

    DATED: October 6, 2023
     
       
     
    Oaktree-TCDRS Strategic Credit, LLC
       
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree-Forrest Multi-Strategy, LLC
         
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree-TBMR Strategic Credit Fund C, LLC
       
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President


    Page 32 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    Oaktree-TBMR Strategic Credit Fund F, LLC
       
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree-TBMR Strategic Credit Fund G, LLC
       
     
    By:
    Oaktree Capital Management, L.P.
       
    Its: Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree-TSE 16 Strategic Credit, LLC
       
     
    By:
    Oaktree Capital Management, L.P.
     
     Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    INPRS Strategic Credit Holdings, LLC


    Page 33 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Manager
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree Gilead Investment Fund AIF (Delaware), L.P.
       
     
    By:
    Oaktree Fund AIF Series, L.P. – Series T
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP AIF, LLC
     
    Its:
    Managing Member
     
    By:
    Oaktree Fund GP III, L.P.
     
    Its:
    Managing Member
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Authorized Signatory
           
     
    Oaktree Specialty Lending Corporation
       
     
    By:
    Oaktree Fund Advisors, LLC
     
    Its:
    Investment Adviser
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree Strategic Credit Fund
       
     
    By:
    Oaktree Fund Advisors, LLC
     
    Its:
    Investment Adviser


    Page 34 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree GCP Fund Delaware Holdings, L.P.
       
     
    By:
    Oaktree Global Credit Plus Fund GP, L.P.
     
    Its:
    General Partner
     
    By:
    Oaktree Global Credit Plus Fund GP Ltd.
     
    Its:
    General Partner
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Director
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
         
     
    Oaktree Diversified Income Fund, Inc.
     
    By:
    Oaktree Fund Advisers, LLC
     
    Its:
    Investment Adviser
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Oaktree AZ Strategic Lending Fund, L.P.
       
     
    By:
    Oaktree AZ Strategic Lending Fund GP, L.P.
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP IIA, LLC
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP II, L.P.
     
    Its:
    Managing Member


    Page 35 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Authorized Signatory
           
     
    Oaktree Loan Acquisition Fund, L.P.
       
     
    By:
    Oaktree Fund GP IIA, LLC
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP II, L.P.
     
    Its:
    Managing Member
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Authorized Signatory
           
     
    Oaktree LSL Fund Holdings EURRC S.à r.l.
         
     
    By:
    /s/ Martin Eckel
       
    Name:
    Martin Eckel
       
    Title:
    Manager
           
     
    Oaktree LSL Fund Delaware Holdings EURRC, L.P.
       
     
    By:
    Oaktree Life Sciences Lending Fund GP, L.P.
     
    Its:
    General Partner
     
    By:
    Oaktree Life Sciences Lending Fund GP Ltd.
     
    Its:
    General Partner
     
    By:
    Oaktree Capital Management, L.P.
     
    Its:
    Director
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President


    Page 36 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    Oaktree PRE Life Sciences, L.P.
       
     
    By:
    Oaktree PRE Life Sciences Fund GP, L.P.
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP IIA, LLC
     
    Its:
    General Partner
     
    By:
    Oaktree Fund GP II, L.P.
     
    Its:
    Managing Member
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Authorized Signatory
         
     
    Oaktree Capital Group, LLC
         
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Atlas OCM Holdings, LLC
     
    By:
    /s/ Henry Orren
       
    Name:
    Henry Orren
       
    Title:
    Senior Vice President
           
     
    Brookfield Corporation
       
     
    By:
    /s/ Swati Mandava
       
    Name:
    Swati Mandava
       
    Title:
    Managing Director, Legal & Regulatory
           
     
    BAM Partners Trust


    Page 37 of  37
    SCHEDULE 13D
    CUSIP No. 45258K109
     
    By:
    BAM Class B Partners Inc.
     
    Its:
    Trustee
         
     
    By:
    /s/ Kathy Sarpash
       
    Name:
    Kathy Sarpash
       
    Title:
    Secretary
           
     
    Brookfield Asset Management ULC
       
     
    By:
    /s/ Kathy Sarpash
       
    Name:
    Kathy Sarpash
       
    Title:
    Managing Director, Legal & Regulatory



    Get the next $IMPL alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $IMPL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $IMPL
    Financials

    Live finance-specific insights

    See more
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals to Report First Quarter 2023 Financial Results on Friday, May 12, 2023

      SEATTLE, May 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced it will host a live webcast on Friday, May 12, 2023, at 8:30 a.m. ET to report its first quarter 2023 financial results and provide a business update. To access the live conference call, please register using the conference link: https://register.vevent.com/register. A live webcast of the event will be available on the Investors section of the Impel Pharmaceuticals website at https://investors.impelpharma.com/. A replay of the webcast and accompan

      5/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 58.4K in 2022; nTRx Increased by 19.4% in Q4 vs. Q3 2022 Net Product Revenue Finished Year at $12.7 Million; Increased 62% in Q4 vs. Q3 2022 to $5 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, March 24, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage pharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a business update. "We continued to see strong growth in Trudhesa® prescriptions as we moved i

      3/24/23 8:17:18 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for TRUDHESA issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/13/21 2:21:35 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for DIHYDROERGOTAMINE MESYLATE issued to IMPEL NEUROPHARMA INC

      Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer

      9/7/21 1:04:43 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      12/4/23 5:12:05 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      11/15/23 4:06:46 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Impel Pharmaceuticals Inc. (Amendment)

      SC 13D/A - IMPEL PHARMACEUTICALS INC (0001445499) (Subject)

      10/6/23 5:10:06 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $IMPL
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $IMPL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $IMPL
    SEC Filings

    See more

    $IMPL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $IMPL
    Leadership Updates

    Live Leadership Updates

    See more
    • Impel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate Sale

      Patient Access to Trudhesa® to Continue Uninterrupted Sufficient Liquidity to Fund Day to Day Operations During Court-Supervised Process SEATTLE, Dec. 19, 2023 /PRNewswire/ -- Impel Pharmaceuticals Inc. (OTCQX:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it is pursuing a sale of the Company and has entered into an agreement with JN BIDCO LLC to serve as the "stalking horse" bidder to acquire the Company and its assets.

      12/19/23 11:10:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Exploration of Strategic Alternatives

      SEATTLE, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL) ("Impel" or "the Company"), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced that it has initiated an exploration of strategic alternatives. As part of this process, the Company plans to consider a wide range of options with a focus on maximizing shareholder value, including a potential sale of assets of the Company, a sale of all of the Company, a merger or other strategic transactions. As the Company explores strategic options, Impel continues to provide full commercial support

      10/5/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces First Quarter 2023 Financial Results and Provides Business Update

      Trudhesa® Achieved nTRx of Over 18.5K in Q1 2023; Increase of 112% vs. Q1 2022 Trudhesa Net Product Revenue in Q1 2023 Increased 149% vs. Q1 2022 to $4.4 Million Impel to Host Investor Conference Call Today at 8:30 a.m. ET SEATTLE, May 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals Inc. (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today reported financial results for the first quarter ended March 31, 2023 and provided a business update. "Following our strategic reprioritization to focus the company on maximizing the growth potential of

      5/12/23 8:00:00 AM ET
      $IMPL
      $CINC
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Smith Brandon D

      3 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/26/23 4:32:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vivo Capital Viii, Llc sold $74,131 worth of shares (575,000 units at $0.13) (SEC Form 4)

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/19/23 6:00:01 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Brookfield Corp /On/

      4 - IMPEL PHARMACEUTICALS INC (0001445499) (Issuer)

      12/4/23 9:00:40 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Impel Pharmaceuticals Inc.

      EFFECT - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/16/24 12:15:09 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:21:28 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 POS filed by Impel Pharmaceuticals Inc.

      S-8 POS - IMPEL PHARMACEUTICALS INC (0001445499) (Filer)

      2/14/24 5:19:30 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on Impel NeuroPharma with a new price target

      Cowen initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $35.00

      5/18/21 7:57:51 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Wedbush initiated coverage on Impel NeuroPharma with a new price target

      Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Guggenheim initiated coverage on Impel NeuroPharma with a new price target

      Guggenheim initiated coverage of Impel NeuroPharma with a rating of Buy and set a new price target of $32.00

      5/18/21 7:55:03 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Appointment of Michael W. Kalb as Chief Financial Officer

      SEATTLE, May 10, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage biopharmaceutical company with a mission to develop transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Michael W. Kalb, CPA, as Chief Financial Officer, effective May 10, 2023. "Michael brings an outstanding track record of executive leadership in finance, capital raising, business development and operations management to Impel Pharmaceuticals," said Adrian Adams, Chairman of the Board and Chief Executive Officer of Impel Pharmaceuticals. "We are delighted to welcome Michael to Impel's leadership team and believe that

      5/10/23 8:00:00 AM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Impel Pharmaceuticals Announces Appointment of Darren Cline to the Board of Directors

      SEATTLE, April 12, 2023 (GLOBE NEWSWIRE) -- Impel Pharmaceuticals (NASDAQ:IMPL), a commercial-stage pharmaceutical company developing transformative therapies for people suffering from diseases with high unmet medical needs, today announced the appointment of Darren Cline to the Board of Directors. Mr. Cline brings more than 30 years of experience in the biopharmaceutical industry, including extensive commercialization and operational expertise. The Company also announced the departure of H. Stewart Parker, with both changes to the Board effective immediately. "It is my pleasure to welcome Darren to the Impel Board of Directors," said Adrian Adams, Chairman of the Board and Chief Executiv

      4/12/23 4:01:00 PM ET
      $IMPL
      Biotechnology: Pharmaceutical Preparations
      Health Care